Skip to content
Disclosery

CHI Advisors LLC

Follow

13F filer, CIK 1791468, NEW YORK, NY

CHI Advisors LLC reported $252,306,335 across 28 holdings for the quarter ended 2023-09-30, in a 13F-HR filed 2023-11-13. Its ten largest share positions make up 81.4% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001085146-23-004322

Period
2023-09-30
Reported value
$252M
Holdings
28
Top 10 weight
81.4%
New
5
Sold out
3

Largest buys vs the previous quarter

SecurityShares changeApprox. value
ORCHARD THERAPEUTICS PLCadded+11,559,916$13.2M
MLYSnew+568,379$5.41M
BLUEPRINT MEDICINES CORPnew+92,888$4.66M
RAREadded+130,000$4.63M
MLTXnew+60,000$3.42M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
VECTIVBIO HLDG AGexited-2,782,756-$46.9M
IRONreduced-100,139-$4.7M
ACELYRIN INCreduced-400,816-$4.08M
DIREXION SHS ETF TRreduced-100,000-$2.06M
PLRXreduced-102,818-$1.78M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q3 2023

Share positions as resolved from 13F-HR 0001085146-23-004322, largest first. % of portfolio is the value over $252,093,835, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
PLRXPLIANT THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: 2,569,479 shares; 2022Q1: 2,657,457 shares; 2022Q2: 3,106,807 shares; 2022Q3: 3,409,758 shares; 2022Q4: 3,169,892 shares; 2023Q1: 3,001,835 shares; 2023Q2: 3,117,017 shares; 2023Q3: 3,014,199 shares 3,014,199$52.3M20.73%-102,818Timeline
REPARE THERAPEUTICS INCREPARE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: 2,212,256 shares; 2022Q1: 2,581,097 shares; 2022Q2: 2,646,781 shares; 2022Q3: 3,069,847 shares; 2022Q4: 2,800,126 shares; 2023Q1: 2,997,939 shares; 2023Q2: 2,998,734 shares; 2023Q3: 2,966,674 shares 2,966,674$35.8M14.22%-32,060
CGEMCULLINAN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: 2,476,720 shares; 2022Q1: 2,753,047 shares; 2022Q2: 3,047,609 shares; 2022Q3: 3,243,185 shares; 2022Q4: 3,317,544 shares; 2023Q1: 3,349,460 shares; 2023Q2: 3,414,189 shares; 2023Q3: 3,414,189 shares 3,414,189$30.9M12.26%0Timeline
ACELYRIN INCACELYRIN INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: not reported; 2022Q1: not reported; 2022Q2: not reported; 2022Q3: not reported; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: 2,663,806 shares; 2023Q3: 2,262,990 shares 2,262,990$23M9.13%-400,816
ORCHARD THERAPEUTICS PLCORCHARD THERAPEUTICS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: not reported; 2022Q1: not reported; 2022Q2: not reported; 2022Q3: not reported; 2022Q4: not reported; 2023Q1: 785,738 shares; 2023Q2: 755,738 shares; 2023Q3: 12,315,654 shares 12,315,654$14M5.57%+11,559,916
LRMRLARIMAR THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: 1,515,148 shares; 2022Q1: 1,515,148 shares; 2022Q2: 1,515,148 shares; 2022Q3: 3,415,148 shares; 2022Q4: 3,473,366 shares; 2023Q1: 2,746,265 shares; 2023Q2: 3,414,468 shares; 2023Q3: 3,414,468 shares 3,414,468$13.5M5.35%0Timeline
KROSKEROS THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: 17,518 shares; 2022Q1: 62,229 shares; 2022Q2: 103,429 shares; 2022Q3: 200,229 shares; 2022Q4: 215,059 shares; 2023Q1: 261,059 shares; 2023Q2: 402,118 shares; 2023Q3: 407,633 shares 407,633$13M5.15%+5,515Timeline
IKENA ONCOLOGY INCIKENA ONCOLOGY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: 814,756 shares; 2022Q1: 814,755 shares; 2022Q2: 1,090,937 shares; 2022Q3: 1,214,304 shares; 2022Q4: 1,637,372 shares; 2023Q1: 1,660,872 shares; 2023Q2: 2,122,040 shares; 2023Q3: 2,180,934 shares 2,180,934$9.44M3.75%+58,894
RAREULTRAGENYX PHARMACEUTICAL INQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: not reported; 2022Q1: not reported; 2022Q2: not reported; 2022Q3: not reported; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: 85,000 shares; 2023Q3: 215,000 shares 215,000$7.66M3.04%+130,000Timeline
CMPXCOMPASS THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: 3,023,692 shares; 2022Q1: 2,829,712 shares; 2022Q2: 2,829,712 shares; 2022Q3: 2,829,712 shares; 2022Q4: 2,829,712 shares; 2023Q1: 2,829,712 shares; 2023Q2: 2,829,712 shares; 2023Q3: 2,829,712 shares 2,829,712$5.57M2.21%0Timeline
MLYSMINERALYS THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: not reported; 2022Q1: not reported; 2022Q2: not reported; 2022Q3: not reported; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: 568,379 shares 568,379$5.41M2.14%newTimeline
INOZYME PHARMA INCINOZYME PHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: 892,057 shares; 2022Q1: 892,057 shares; 2022Q2: 2,033,802 shares; 2022Q3: 1,996,277 shares; 2022Q4: 2,204,876 shares; 2023Q1: 1,342,191 shares; 2023Q2: 1,195,027 shares; 2023Q3: 1,270,027 shares 1,270,027$5.33M2.12%+75,000
SYRSSYROS PHARMACEUTICALS INC COMQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: not reported; 2022Q1: not reported; 2022Q2: not reported; 2022Q3: not reported; 2022Q4: not reported; 2023Q1: 767,445 shares; 2023Q2: 767,445 shares; 2023Q3: 1,299,359 shares 1,299,359$5.12M2.03%+531,914Timeline
BLUEPRINT MEDICINES CORPBLUEPRINT MEDICINES CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: not reported; 2022Q1: not reported; 2022Q2: not reported; 2022Q3: not reported; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: 92,888 shares 92,888$4.66M1.85%new
DIREXION SHS ETF TRDIREXION SHS ETF TRQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: not reported; 2022Q1: not reported; 2022Q2: not reported; 2022Q3: 50,000 shares; 2022Q4: 25,000 shares; 2023Q1: not reported; 2023Q2: 325,000 shares; 2023Q3: 225,000 shares 225,000$4.63M1.84%-100,000
2SEVENTY BIO INC COMMON STO…2SEVENTY BIO INC COMMON STOCKQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: not reported; 2022Q1: 819,672 shares; 2022Q2: 819,672 shares; 2022Q3: 530,223 shares; 2022Q4: 333,252 shares; 2023Q1: 855,000 shares; 2023Q2: 852,007 shares; 2023Q3: 1,002,007 shares 1,002,007$3.93M1.56%+150,000
MLTXMOONLAKE IMMUNOTHERAPEUTICSQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: not reported; 2022Q1: not reported; 2022Q2: not reported; 2022Q3: not reported; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: 60,000 shares 60,000$3.42M1.36%newTimeline
OVIDOVID THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: 400,000 shares; 2022Q1: 852,888 shares; 2022Q2: 864,822 shares; 2022Q3: 864,822 shares; 2022Q4: 864,822 shares; 2023Q1: 864,822 shares; 2023Q2: 864,822 shares; 2023Q3: 864,822 shares 864,822$3.32M1.32%0Timeline
SGMTSAGIMET BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: not reported; 2022Q1: not reported; 2022Q2: not reported; 2022Q3: not reported; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: 348,842 shares 348,842$3.07M1.22%newTimeline
OMEGA THERAPEUTICS INCOMEGA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: 1,055,882 shares; 2022Q1: 1,055,882 shares; 2022Q2: 1,055,882 shares; 2022Q3: 1,055,882 shares; 2022Q4: 1,055,882 shares; 2023Q1: 1,055,882 shares; 2023Q2: 1,055,882 shares; 2023Q3: 1,055,882 shares 1,055,882$2.27M0.9%0
BDTXBLACK DIAMOND THERAPEUTICS IQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: not reported; 2022Q1: not reported; 2022Q2: not reported; 2022Q3: not reported; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: 750,000 shares; 2023Q3: 720,000 shares 720,000$2.07M0.82%-30,000Timeline
RALLYBIO CORPRALLYBIO CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: not reported; 2022Q1: not reported; 2022Q2: not reported; 2022Q3: 194,297 shares; 2022Q4: 726,109 shares; 2023Q1: 760,543 shares; 2023Q2: 542,774 shares; 2023Q3: 390,734 shares 390,734$1.32M0.52%-152,040
IRONDISC MEDICINE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: not reported; 2022Q1: not reported; 2022Q2: not reported; 2022Q3: not reported; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: 125,139 shares; 2023Q3: 25,000 shares 25,000$1.17M0.47%-100,139Timeline
GRAPHITE BIO INCGRAPHITE BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: not reported; 2022Q1: not reported; 2022Q2: not reported; 2022Q3: not reported; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: 230,938 shares; 2023Q3: 230,938 shares 230,938$573K0.23%0
FREELINE THERAPEUTICS HLDGSFREELINE THERAPEUTICS HLDGSQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: not reported; 2022Q1: not reported; 2022Q2: not reported; 2022Q3: not reported; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: 21,666 shares; 2023Q3: 86,654 shares 86,654$373K0.15%+64,988
PRECISION BIOSCIENCES INCPRECISION BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: 606,629 shares; 2022Q1: 606,629 shares; 2022Q2: 3,003,751 shares; 2022Q3: 3,674,820 shares; 2022Q4: 3,549,820 shares; 2023Q1: 3,469,820 shares; 2023Q2: 1,603,557 shares; 2023Q3: 606,629 shares 606,629$207K0.08%-996,928

Options

Puts and calls, as filed. The amount and value describe the underlying shares, not the option premium, so they stay out of % of portfolio (H5).

SecurityTypeAmountValueChange
REPARE THERAPEUTICS INCREPARE THERAPEUTICS INC COMcall50,000$158Knew
PLRXPLIANT THERAPEUTICS INC COMcall137,500$55K+7,200

Sold out in Q3 2023

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
VECTIVBIO HLDG AGVECTIVBIO HLDG AG2,782,756$46.9Mshares
HOOKIPA PHARMA INCHOOKIPA PHARMA INC788,740$694Kshares
CRVSCORVUS PHARMACEUTICALS INC200,000$458Kshares

How Q3 2023 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001085146-23-004322 base2023-11-13acceptance time not in the bulk data set

Filings

Every filing of this filer: 13F reports and notices, the 13D and 13G it filed or is a reporting person of, and Forms 3, 4 and 5 it reported as an owner.

FilingSubjectFiledAcceptedIngested
13F-HR 0001085146-23-004322 Quarter ended 2023-09-302023-11-13acceptance time not in the bulk data set
13F-HR/A 0001085146-23-003476 Quarter ended 2023-06-302023-08-22acceptance time not in the bulk data set
13F-HR 0001085146-23-003260 Quarter ended 2023-06-302023-08-11acceptance time not in the bulk data set
13F-HR 0001085146-23-002240 Quarter ended 2023-03-312023-05-11acceptance time not in the bulk data set
13F-HR 0001085146-23-001058 Quarter ended 2022-12-312023-02-13acceptance time not in the bulk data set
13F-HR 0001085146-22-003844 Quarter ended 2022-09-302022-11-09acceptance time not in the bulk data set
13F-HR 0001085146-22-003022 Quarter ended 2022-06-302022-08-12acceptance time not in the bulk data set
13F-HR 0001085146-22-002173 Quarter ended 2022-03-312022-05-16acceptance time not in the bulk data set
13F-HR 0001085146-22-000838 Quarter ended 2021-12-312022-02-11acceptance time not in the bulk data set
13F-HR 0001085146-21-003316 Quarter ended 2021-09-302021-11-15acceptance time not in the bulk data set
13F-HR 0001085146-21-002377 Quarter ended 2021-06-302021-08-11acceptance time not in the bulk data set
13F-HR 0001085146-21-001643 Quarter ended 2021-03-312021-05-14acceptance time not in the bulk data set
13F-HR 0001085146-21-000719 Quarter ended 2020-12-312021-02-12acceptance time not in the bulk data set
13F-HR 0001085146-20-002863 Quarter ended 2020-09-302020-11-12acceptance time not in the bulk data set
13F-HR/A 0001085146-20-002347 Quarter ended 2020-06-302020-08-17acceptance time not in the bulk data set
13F-HR 0001085146-20-002159 Quarter ended 2020-06-302020-08-12acceptance time not in the bulk data set
13F-HR 0001085146-20-001506 Quarter ended 2020-03-312020-05-14acceptance time not in the bulk data set
13F-HR 0001085146-20-000845 Quarter ended 2019-12-312020-02-14acceptance time not in the bulk data set
13F-HR 0001085146-19-002865 Quarter ended 2019-09-302019-11-12acceptance time not in the bulk data set